Inhibitor 56 and structurally similar thiourea derivativesare also reported in a patent of the Scripps Research Institute, inwhich these ABHD12 inhibitors were claimed as useful for the treatmentof cancer, neuropsychiatric disorders, and neurodegenerative, autoimmune,neuroinflammatory, and infectious diseases.199 Besides 56, the most promising compounds are compounds 57, 58, and 59 (Figure 14), which displayed IC50 values lower than or equal to 100 nM for ABHD12 inhibitionin competitive ABPP assays and in a substrate-based assay by usingHEK293T cells overexpressing ABHD12. This evidence concerns the gene ABHD12 and infectious disease.